Result of phase II clinical trial of herceptin in advanced Chinese breast cancer patients.
- Author:
Yan SUN
1
;
Li-qing LI
;
San-tai SONG
;
Li-gong XU
;
Shi-ying YU
;
Jin-wan WANG
;
Ze-fei JIANG
;
Ji-liang YIN
;
Hui-hua XIONG
Author Information
- Publication Type:Clinical Trial
- MeSH: Adult; Aged; Antibodies, Monoclonal; adverse effects; therapeutic use; Antibodies, Monoclonal, Humanized; Breast Neoplasms; drug therapy; Female; Humans; Middle Aged; Trastuzumab
- From: Chinese Journal of Oncology 2003;25(6):581-583
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo observe the clinical efficacy and adverse effects of herceptin for advanced Chinese breast cancer patients.
METHODSThirty-one pathologically proved advanced breast cancer women were treated by herceptin. In the first week, a loading dose 4 mg/kg was administered by intravenous infusion and from the second week, a routine dose of 2 mg/kg was given every week for at least 3 months.
RESULTSThere were 2 CR, 6 PR, 7 SD, and 16 PD among 31 patients after treatment by herceptin, the response rate being 25.8%. In factors influencing the prognosis, age and general condition were factors favoring the results, and pathological type, site of metastasis, grade of her-2 over expression and prior treatment were irrelevant to the results. The adverse effects were mild but different from those of the common anticancer drugs.
CONCLUSIONHerceptin is effective and well tolerated by the Chinese breast cancer patients.
